Document Detail

The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
MedLine Citation:
PMID:  19178601     Owner:  NLM     Status:  MEDLINE    
Among the most commonly used therapies to treat pulmonary arterial hypertension (PAH) are the prostanoids. Epoprostenol, a relatively effective therapy for PAH, has its limitations, which are largely attributable to its pharmacokinetic properties and its requirement for intravenous administration. The development of an equally effective oral prostanoid would be an important advance in the PAH armamentarium. An early generation oral prostanoid, beraprost, was previously demonstrated to have modest, transient clinical benefits, but at the cost of a high proportion of intolerable side effects. TRK-100STP is a newer generation oral prostanoid currently under clinical investigation.
J Rich; M M Hoeper
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of clinical practice. Supplement     Volume:  -     ISSN:  1368-504X     ISO Abbreviation:  Int J Clin Pract Suppl     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-01-30     Completed Date:  2009-10-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9712380     Medline TA:  Int J Clin Pract Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-8     Citation Subset:  IM    
University of Chicago Hospitals, Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Drug Discovery
Epoprostenol / analogs & derivatives,  therapeutic use
Hypertension, Pulmonary / drug therapy*
Prostaglandins / therapeutic use*
Randomized Controlled Trials as Topic / methods
Research Design
Treatment Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/Prostaglandins; 35121-78-9/Epoprostenol; 88430-50-6/beraprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  What we know and what we would like to know about genetics and pulmonary arterial hypertension.
Next Document:  HIV-associated pulmonary arterial hypertension: a clinical problem that is here to stay?